Triple meeting 2024 – can Revolution succeed where others stumbled?
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
Venture-backed biotechs push into the clinic
The latest first-in-human study initiations will be of interest to followers of D2M Therapeutics, Nested and Volastra.
